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REPRESENTiNg THE THRESHOlD iN THE COST-EffECTivENESS PlANE: 
PROPOSiNg A NEw gRAPHiCAl CONvENTiON
O’Mahony JF
Trinity College Dublin, Dublin, Ireland
BAckground: The aim of this presentation is to explain why the standard cost-
effectiveness (CE) plane gives an incomplete representation of the cost-effective-
ness of intervention strategies and to show how this problem is easily solved. The 
CE plane is the standard graphical framework for presenting costs, effects and 
incremental cost-effectiveness ratios (ICERs) of alternative intervention strategies. 
Comparing multiple strategies typically yields an increasingly steep efficient fron-
tier, indicating that strategies become progressively less cost-effective as the ICER 
rises. However, standard CE planes generally do not include the cost-effectiveness 
threshold, therefore the figure itself does not identify which strategies are cost-
effective. Consequently, the CE plane does not make it clear what strategy is optimal 
and the relative scale of costs and effects in the figure is uninformative. AnALYSIS: 
A new graphical convention is proposed whereby a line with slope equal to the cost-
effectiveness threshold is added to the CE plane. While previous examples of CE 
planes have included such threshold lines, these have drawn the threshold from the 
origin, often at 45 degrees. Using published cost-effectiveness estimates from the 
literature, we show why this approach can be problematic: it does not readily iden-
tify the optimal strategy; can confuse average and incremental cost-effectiveness 
ratios; and, can impose a scale on the diagram that obscures relevant detail. Using 
the same published examples we then demonstrate the proposed alternative of 
including a threshold line which is set tangential to the frontier rather than passing 
through the origin and is not necessarily drawn at 45 degrees. This unambiguously 
identifies the optimal strategy and provides a useful scale that graphically illustrates 
which interventions are cost-effective. concLuSIon: The simple inclusion of the 
threshold avoids several problems with the CE plane. It enhances the usefulness of 
the figure and better communicates which strategies are relevant and which are not.
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BAckground: Chronic Obstructive Pulmonary Disease (COPD) is the third main 
cause of death worldwide (WHO, 2014). For 2013, in Portugal 2,720 deaths were 
associated to COPD. Smoking is the main risk-factor and smoking cessation is 
the most effective strategy to slowdown the progression of COPD. oBjectIve: To 
model the health benefits associated to early diagnosis and treatment of COPD in 
Portugal over a 20 year time-horizon. MethodS: Using a stochastic individually 
based dynamic microsimulation model, health benefits were estimated as the dif-
ference in health outcomes between an intervention scenario and the status quo. 
The intervention considered is a screening program of smokers and ex-smokers 
aged 40 and over in primary healthcare settings, with selective referral to smoking 
cessation programs. In each scenario the model identifies: a) population with-
out COPD (NO-COPD); b) population with a COPD diagnosis (COPD-DIAG) and c) 
population with undiagnosed COPD (COPD-NODIAG). The calibration of the model 
assumes the mean forced expiratory volume in one second (FEV1) in individuals 
with COPD follows a normal distribution, as suggested by the literature. Following 
the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, four 
severity stages were identified depending on the FEV1 value. Exacerbation fre-
quency and quality of life differ according to the stage of the individual. In each 
year, NO-COPD individuals have probabilities of transitioning to COPD according 
to sex, age and smoking habits; the FEV1 declines according to previous FEV1 level, 
smoking cessation and exacerbation episodes. Compared to COPD-NODIAG, the 
progression of the COPD-DIAG population is slower and quality of life higher due 
to medication and fewer exacerbation episodes per year. concLuSIonS: Early 
diagnosis and treatment of COPD may lead to substantial health gains. Modelling 
the disease evolution in order to assess the impact of future interventions is 
crucial to guide policy.
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HOw TO CAlCulATE vAluE Of iNfORMATiON iN SECONDS uSiNg ‘SAvi’, THE 
SHEffiElD ACCElERATED vAluE Of iNfORMATiON wEB APP
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University of Sheffield, Sheffield, UK
BAckground: Health economic models are used to estimate the expected costs 
and health outcomes of competing decision options. Model parameters are gener-
ally uncertain, and it is often useful to quantify the value of undertaking further 
data collection in order to reduce uncertainty. An upper bound on the value of 
resolving all uncertainty regarding an input parameter is quantified by its partial 
Expected Value of Perfect Information (EVPI). The value of a specific future study 
is quantified by its Expected Value of Sample Information (EVSI). PROBLEM: The 
standard approach to computing both partial EVPI and EVSI is via a nested two-
level Monte Carlo scheme that includes at each inner loop step both parameter 
sampling and model evaluation. This scheme can be prohibitively slow for complex 
models (eg. patient-level simulation models). Additional difficulties may occur in 
the calculation of EVSI if we have to resort to Markov-chain Monte Carlo (eg. using 
WinBUGS) to generate samples from the posterior distribution of the parameters 
given the simulated data for our proposed study. These difficulties have resulted in 
the restriction of Value of Information analyses to a small subset of health economic 
evaluations. SOLUTION: We have developed fast non-parametric regression based 
methods for computing both partial EVPI and EVSI. For partial EVPI we require only 
oBjectIveS: Remote monitoring (RM) is useful in chronic diseases, but evidence 
is scarce in home dialysis. Sharesource™, a two way connectivity platform with 
RM capabilities, should enable earlier intervention and healthcare savings. This 
abstract describes a simulation study designed to estimate the type and impor-
tance of the savings. MethodS: This study used an approach similar (although 
in a virtual environment) to that for diagnostic tests, i.e., additional information 
impact on treatment pathways. Automated peritoneal dialysis (APD) patient pro-
files (e.g., therapy non-compliance, fluid overload, etc.) were developed by a group 
of in-house nephrologists and nurses experienced in managing APD patients. Each 
patient profile was developed in 2 scenarios: “with RM” information (treatment 
data, blood pressure, weight) and “without RM”. Nephrologist (US= 4, Germany= 3, 
Italy= 2) experts in managing APD patients validated the “without RM” resources. 
The “with RM” resources were evaluated by 15 (US= 7, Germany= 4, Italy= 4) APD 
teams (1 nephrologist & 1 nurse). Resources were compared with t-tests. reSuLtS: 
Patient profile development required several rounds of individual and group 
reviews over a 6 month-period to ensure clarity of clinical event sequence and 
clinician management response. During the process, 8 profiles were abandoned, 
leaving 12 profiles for the simulation. Recruitment of experts and APD teams was 
moderately easy, the biggest hurdle was contract signature in some countries 
(e.g., Italy). Participants submitted responses, usually within two weeks. Overall, 
results indicate that RM could avoid 49-75 healthcare resources (4.1-6.2 per patient 
profile), including clinic calls/visits (48-72), but also hospitalizations (2), emer-
gency room visits (3.5-5) and transfer from APD to in-center hemodialysis (1-2.25). 
These patient profiles were perceived as representative of 17-37% of the APD 
patient population. concLuSIonS: This simulation was a rapid and affordable 
way of estimating the type and importance of potential reductions in healthcare 
resource consumption to be expected from RM in APD patients while waiting for 
real-world evidence.
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oBjectIveS: To investigate types of study design associated with classifications 
of either good or poor quality as defined by QUADAS-2, a new tool developed by 
Bristol University and used in decision-making evaluations for diagnostic technol-
ogy. MethodS: A pragmatic review of studies in Medline, Embase and the Cochrane 
Library was conducted to identify the widest possible variety of study designs used 
in the autoimmune disease therapeutic area. Using QUADAS-2, each study was 
assessed for a high, low or unclear risk of bias across four domains: patient selec-
tion, index test, reference standard and patient flow. reSuLtS: A number of study 
design features in the autoimmune disease area heavily influenced the risk of bias. 
Avoidance of a case-control design had the greatest impact overall. For example, 
case-control designs that enroll participants with known disease and include a 
control group without the condition may exaggerate diagnostic accuracy (patient 
selection domain), and they would make it more likely that biomarker assessment 
would be conducted with knowledge of the clinical diagnosis (index test domain). In 
contrast, a non-case-control design would mean that clinical assessment of the dis-
ease would be performed without knowledge of the results of the biomarker assess-
ment, leading to a low risk of bias (reference standard domain). concLuSIonS: 
Avoidance of a case-control study design had the biggest impact on QUADAS-2 
assessment of risk of bias in autoimmune disease diagnostic studies. Studies which 
exclude difficult-to-diagnose patients, such as those presenting with symptoms in a 
genuine diagnostic setting, may over-estimate test sensitivity. It is critical to adhere 
to design features leading to a low risk of bias because decision makers will review 
the quality of diagnostic accuracy studies based on QUADAS-2.
PRM242
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oBjectIveS: Health technology assessment (HTA) agencies apply different impor-
tance to different aspects of HTA submissions. It is therefore difficult to draw gen-
eralizable conclusions about the factors influencing subsequent recommendations. 
Previous studies have tried to identify country-specific factors, but there were differ-
ent techniques and parameters applied. The aim of this literature review is therefore 
to collate all parameters used in previous research in order to inform research into 
the predictive factors for HTA recommendations. MethodS: A systematic literature 
review was performed using PubMed. Examples of search terms used are “success”, 
“HTA” and “recommendation”. The time span was from 2004 to 2015. The studies 
differed in terms of methods used, parameters used and research questions. After 
the quality of the articles was assessed, the evidence provided in the literature was 
summarized and the findings were interpreted. The parameters analysed in the stud-
ies were compared taking into account country-specific requirements. reSuLtS: Out 
of sixteen articles identified, most studies evaluated NICE (six studies), followed by 
PBAC (four studies). The remaining studies evaluated different countries. A total of 
111 parameters were identified, which were grouped in three categories: clinical, 
economic and societal factors. The predictive clinical factors showed some regular-
ity explaining the HTA recommendation. Drug superiority, RCTs and the number of 
comparators were reoccurring explanatory variables. Economic factors showed most 
consistency among the studies. For NICE, cost-effectiveness proved to be an explana-
tory factor in all studies. Societal parameters were identified less often as explanatory 
factors, but included the burden of illness and company size. concLuSIonS: Many 
parameters have been used in previous research to explain the HTA decision, but 
there is no agreement yet on the driving parameters explaining the HTA-decision per 
agency. Hardly any study investigated an agency different than NICE or PBAC, which 
indicates that there is a knowledge gap for other agencies.
